>>

>>

抑制剂/激活剂

>>

凋亡与自噬

>>

Oxaliplatin 奥沙利铂

Oxaliplatin 是一种 DNA 合成抑制剂。Oxaliplatin 会导致 DNA 交联损伤，阻止 DNA 复制和转录并导致细胞死亡。Oxaliplatin 以时间依赖方式抑制人黑色素瘤细胞系 C32 和 G361，IC50 值分别为 0.98 μM 和 0.14 μM。Oxaliplatin 可以诱导细胞自噬 (autophagy)。

货号：
TK0243
规格：

5mg

50mg

100mg
价格：
￥0.00

产品参数

CAS No.	61825-94-3
生物活性	Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and causes cell death. Oxaliplatin time-dependently inhibits human melanoma cell lines C32 and G361 with IC50 values of 0.98 μM and 0.14 μM, respectively. Oxaliplatin induces cell autophagy.
分子式	C8H14N2O4Pt
分子量	397.29
运输条件	Room temperature in continental US; may vary elsewhere.
储存条件	4°C, protect from light
溶解性数据	H2O : 2.17 mg/mL (5.46 mM; ultrasonic and warming and heat to 60°C; DMSO can inactivate Oxaliplatin's activity) DMF : 1.67 mg/mL (4.20 mM; Need ultrasonic; DMSO can inactivate Oxaliplatin's activity) Ethanol : < 1 mg/mL (insoluble; DMSO can inactivate Oxaliplatin's activity)
体内研究	Oxaliplatin (10 mg/kg, i.p.) significantly reduces tumor volume and apoptotic index in the nude mice bearing hepatocellular HCCLM3 tumors. Oxaliplatin (5 mg/kg, i.v.) is effective on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C26 colon carcinoma xenografts. Oxaliplatin induces impairment of retrograde neuronal transport in mice. Oxaliplatin is incompatible with chloride ion. Avoid saline or dextrose/saline diluents.
体外研究	Oxaliplatin acts through the formation of DNA-adducts. Oxaliplatin induces primary and secondary DNA lesions leading to cell apoptosis. Oxaliplatin inhibits human melanoma cell lines C32 and G361 with IC50 values of 0.98 μM and 0.14 μM, respectively. Oxaliplatin potently inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. For storage 5% Glucose can be used as a in vitro preparing solution. You can prepare a 5 mM (2 mg/mL) Oxaliplatin solution (or you can refer to the solubility data on datasheet), chemical and physical in-use stability has been demonstrated for up to 48 hours at 2°C-8°C, 7 days at -20°C.
文献	•Nat Med. 2019 Sep;25(9):1428-1441. •JAMA Oncol. 2021 Nov 18;e215445. •Gastroenterology. 2021 Nov;161(5):1601-1614.e23. •Signal Transduct Target Ther. 2021 May 28;6(1):188. •J Exp Med. 2018 Jan 2;215(1):115-140. •Cancer Res. 2018 Oct 1;78(19):5586-5599. •Proc Natl Acad Sci U S A. 2017 Mar 7;114(10):E1825-E1832. •J Exp Clin Cancer Res. 2021 Sep 22;40(1):297. •J Exp Clin Cancer Res. 2017 Sep 22;36(1):131. •J Control Release. 2021 Mar 1;S0168-3659(21)00107-3. •Cell Rep. 2021 Nov 30;37(9):110069. •Cancer Lett. 2020 Apr 28;476:67-74. •Cell Death Dis. 2021 Oct 6;12(10):911. •Cell Death Dis. 2019 Aug 13;10(8):615. •Cell Death Dis. 2018 May 22;9(6):591. •Cell Chem Biol. 2020 Nov 19;27(11):1359-1370.e8. •J Med Chem. 2021 Jul 8;64(13):9271-9278. •J Med Chem. 2020 Aug 13;63(15):8380-8387. •Mol Oncol. 2020 Nov;14(11):2894-2919. •Biomed Pharmacother. 2018 Jul;103:729-737. •Eur J Med Chem. 2021 Jan 15;210:113080. •Int J Nanomedicine. 2019 Dec 2;14:9377-9393. •Mol Cancer Ther. 2020 Mar;19(3):906-919. •Front Oncol. 2021 Jul 13;11:704042. •Acta Pharmacol Sin. 2021 Jan;42(1):108-114. •Front Cell Neurosci. 2017 Jul 21;11:219 •Stem Cells Int. 23 Nov 2021. •Int J Cancer. 2020 Mar 15;146(6):1700-1716. •Mol Carcinog. 2017 Dec;56(12):2692-2705. •J Mol Med (Berl). 2019 Aug;97(8):1183-1193. •Sci Rep. 2016 Dec 1;6:38267. •Dalton Trans. 2020 May 7;49(17):5703-5710. •Oncol Rep. 2020 Feb;43(2):405-414. •Exp Cell Res. 2020 Aug 1;393(1):112054. •Biochem Biophys Res Commun. 2021 May 27;563:1-7. •Biol Pharm Bull. 2019 Jun 1;42(6):900-905. •Gastroent Res Pract. 2021 Jun 17;2021:5960821. •Int J Clin Exp Pathol. 2017;10(3):3033-3042. •Research Square Preprint. 2021 Oct. •Patent. US10947274. •Institut des Sciences Pharmaceutiques Professeur P. Nowak-Sliwinska de Suisse Occidentale Pharmacologie Moléculaire. 2020 Sep. •Tumour Biol. 2016 Jul;37(7):8811-24.
纯度及产品资料	98%

推荐产品